EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Empagliflozin And Metformin Hydrochloride patents expire, and when can generic versions of Empagliflozin And Metformin Hydrochloride launch?
Empagliflozin And Metformin Hydrochloride is a drug marketed by Zydus Pharms and is included in one NDA.
The generic ingredient in EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
Summary for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 62 |
Patent Applications: | 5 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | Phase 3 |
Handok Inc. | Phase 3 |
Karolinska University Hospital | N/A |
See all EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE clinical trials